Meet the Data: Conversations with Leading Experts on the Role of HCC and Immunotherapy
SIO Meet the Data Series: Explore the evolving landscape of hepatocellular carcinoma treatment in this four-part podcast series, featuring conversations with leading experts on the role of immunotherapy. This series features expert discussions highlighting emerging clinical trial evidence and addressing key knowledge gaps relevant to the implementation of these novel therapeutic regimens into clinical practice.

Episode 4: Ablation vs. Ablation + Combination Immune Therapy

Can combining ablation with immune therapy improve patient outcomes in liver cancer? Experts Gentry King and Isabel Newton examine the latest clinical data comparing ablation alone versus ablation plus immune therapy. Moderated by Elena Violari, the discussion evaluates efficacy, recurrence rates, and synergistic mechanisms, while exploring how cancer stage, tumor location, and genetic markers guide patient selection for these evolving treatment strategies.

Moderator:

• Elena Violari, MD | Loyola University Chicago

Faculty:

• Gentry King, MD | University of Washington

• Isabel G. Newton, MD, PhD | University of California San Diego

Resources

Gentry King, MD

https://www.fredhutch.org/en/provider-directory/gentry-king.html

Isabel G. Newton, MD, PhD

https://providers.ucsd.edu/details/22369/radiology

Checkmate 90W Trial:

https://ascopubs.org/doi/full/10.1200/JCO.22.01436

IMbrave150 Trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2900800-6/fulltext

LEAP-012 Trial:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract

Emerald-Y90 Trial:

https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4221

Disclaimer

This discussion is intended for healthcare professionals for educational purposes only. It does not constitute medical advice and should not replace individualized patient care decisions.